by goldfishadmin | Jun 11, 2022 | News
SAN DIEGO, June 11, 2022 – Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that additional data from...
by goldfishadmin | Aug 31, 2016 | News
Orphagen Pharmaceuticals, Inc., a privately held company, announced today that its partner, Japan Tobacco Inc. (“JT”), has entered Phase I clinical trials with an oral small molecule, JTE-451, for treatment of autoimmune and allergic diseases. This is a major...
by goldfishadmin | Aug 12, 2016 | Pipeline column
Our mission is translational drug discovery and development with novel targets leading to first-in-class industry partnerships....
by goldfishadmin | Aug 12, 2016 | about column
Our scientists and management team are committed to the best we can bring to bear in pursuit of new therapies. We are drug hunters....
by goldfishadmin | Oct 22, 2015 | News
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has awarded the company a highly competitive Phase 1 Small Business Innovative Research...
